Browse by Poster Presenter

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

W
Walker, Brandi

Division of Hematology, Department of Internal Medicine, The Ohio State University
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Brandi Walker
Favorite
Walker, Patricia

Peninsula Health and Peninsula Private Hospital
2010 - Zanubrutinib vs bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Patricia Walker
Favorite
Wallace, Danielle

Wilmot Cancer Institute / University of Rochester Medical Center
1139 - Initial anti-CD20 monoclonal antibody therapy in CLL quickly induces cytokine release syndrome with first dose infusion reaction correlating only with high IL-6, IL-8 and IP-10
Danielle Wallace
Favorite
Walsh, Danielle

The University of Texas MD Anderson Cancer Center
1208 - The HEALTH4CLL study: optimization of behavioral interventions for patients with chronic lymphocytic leukemia
Danielle Walsh
Favorite
Wang, Ching-Kun

COTA, Inc.
1109 - Real world treatment patterns, reasons for discontinuation, and survival outcomes among patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL) receiving second or later lines of therapy in a contemporary population treated in the United States
Ching-Kun Wang
Favorite
Wang, Chunxiao

Eli Lilly and Company
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Chunxiao Wang
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Chunxiao Wang
Favorite
Wang, Denise

Loxo@Lilly
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Denise Wang
Favorite
Wang, Hengbang

Ascentage Pharma (Suzhou) Co., Ltd.
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Hengbang Wang
Favorite
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
Hengbang Wang
Favorite
Wang, Hong-xiang
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Hong-xiang Wang
Favorite
Wang, Hua

2. Department of Hematology, Shandong Provincial Hospital, Shandong University
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Hua Wang
Favorite
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Hua Wang
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Hua Wang
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Hua Wang
Favorite
Wang, Jianxiang

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Jianxiang Wang
Favorite
Wang, Juejin

Nanjing Medical University
1149 - Ibrutinib induces cardiac arrhythmia by targeting CaV1.2 calcium channel
Juejin Wang
Favorite
Wang, Li

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1008 - XPO1 inhibitor Selinexor induces heme oxygenase-1 mediated p53-dependent ferroptosis in chronic lymphocytic leukemia
Li Wang
Favorite
1017 - NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia
Li Wang
Favorite
1047 - Prognosis Analysis and Validation of Fatty Acid Metabolism-Related Signature in Chronic lymphocytic leukemia
Li Wang
Favorite
Wang, Lin

Bristol Myers Squibb
1110 - Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
Lin Wang
Favorite
2021 - Health-related quality of life in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with liso-cel in TRANSCEND CLL 004
Lin Wang
Favorite
Wang, Liping

BeiGene USA, Inc.
2014 - Characterization of the safety/tolerability profile of zanubrutinib and comparison with the profile of ibrutinib in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Liping Wang
Favorite
Wang, Mi

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Mi Wang
Favorite
Wang, Michael

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
Michael Wang
Favorite
Wang, Peilong

Department of Hematology, The Second Xiangya Hospital, Molecular Biology Research Center, School of Life Sciences, Hunan Province Key Laboratory of Basic and Applied Hematology, Central South University
1014 - Clonal architecture and single-cell transcriptome landscape in Richter’s syndrome
Peilong Wang
Favorite
Wang, Qi

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Qi Wang
Favorite
Wang, Ruibin

Janssen Scientific Affairs, LLC
2026 - Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs chemoimmunotherapy
Ruibin Wang
Favorite
2027 - Real-world assessment of dosing patterns and treatment outcomes in patients with chronic lymphocytic leukemia who initiated first-line single-agent ibrutinib in an integrated claims-based database
Ruibin Wang
Favorite
Wang, Shaomeng

Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Shaomeng Wang
Favorite
Wang, Tingyu

Blood Disease Hospital, Chinese Academy of Medical Science
1127 - Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
Tingyu Wang
Favorite
1214 - An Investigation into the Differences between Western and Chinese population with Chronic Lymphocytic Leukemia
Tingyu Wang
Favorite
Wang, Xin

1. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China. 2. Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, 250021, China. 3. Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong, 250021, China. 4. National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, 251006, China.
1018 - Fatty Acid Metabolism Fingerprints Predict Prognosis and Regulate Immunophenotype in Chronic Lymphocytic Leukemia
Xin Wang
Favorite
1029 - Deubiquitinase PSMD14 Promotes Progression of Chronic Lymphocytic Leukemia by Stabilizing CSDE1
Xin Wang
Favorite
1033 - Single-Cell Transcriptome Profiling Reveals Neoplastic Effects of Exosomal S100A4 in Chronic Lymphocytic Leukemia
Xin Wang
Favorite
1035 - ENPP2 mediates lipid metabolism and tumorigenesis in chronic lymphocytic leukemia through AMPK signaling pathway
Xin Wang
Favorite
Wang, Yucai

Mayo Clinic
1121 - Safety of concomitant delivery of radiotherapy for second primary malignancy in patients with chronic lymphocytic leukemia treated with continuous novel agents
Yucai Wang
Favorite
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Yucai Wang
Favorite
1160 - Clinical outcomes in patients with chronic lymphocytic leukemia (CLL) treated with venetoclax-based regimens
Yucai Wang
Favorite
1229 - A Study of Frontline Therapy in Adults Aged 80+ Years with Chronic Lymphocytic Leukemia (CLL)
Yucai Wang
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Yucai Wang
Favorite
3004 - A Phase 2 Study of Minimal Residual Disease-Guided, Time-Limited, First-Line Therapy of Chronic Lymphocytic Leukemia with Pirtobrutinib and Venetoclax (MIRACLE)
Yucai Wang
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Yucai Wang
Favorite
Wang, Zhiquan

Mayo Clinic
1134 - High deletion burden identified by whole genome sequencing is associated with enhanced risk in del17p CLL patients
Zhiquan Wang
Favorite
2006 - Impact of nucleotide metabolism on CLL B-cell pathobiology and CLL disease progression
Zhiquan Wang
Favorite
Wargo, Jennifer

MD Anderson Cancer Center
1137 - Efficacy of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma (AM) in Patients with Concomitant Chronic Lymphocytic Leukemia (CLL)
Jennifer Wargo
Favorite
Warner, Kathrin
1039 - The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL
Kathrin Warner
Favorite
Warren, Edus

Fred Hutchinson Cancer Center
1106 - Clinical Relevance of the Recommended Intensive Laboratory Monitoring during the Standard Ramp-up at Time of Venetoclax Initiation for CLL: A Real-World Experience
Edus Warren
Favorite
Warwick, Lorna

Lymphoma Coalition
1213 - An examination of health literacy amongst patients with Chronic Lymphocytic Leukemia- A study from The Lymphoma Coalition Global Patient Survey 2022.
Lorna Warwick
Favorite
Watson, Amanda
1213 - An examination of health literacy amongst patients with Chronic Lymphocytic Leukemia- A study from The Lymphoma Coalition Global Patient Survey 2022.
Amanda Watson
Favorite
Watson, Talissa

Analysis Group, Inc.
1153 - SWITCHING FROM COVALENT BTKI TO BCL2i IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES COMPARED TO SWITCHING TO A DIFFERENT COVALENT BTKI IN PATIENTS WITH CLL/SLL TREATED IN THE REAL-WORLD SETTING
Talissa Watson
Favorite
Weinkove, Robert

Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand; Malaghan Institute of Medical Research
2017 - Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study
Robert Weinkove
Favorite
Wei, Xiaolei

Department of Hematology, Nanfang Hospital, Southern Medical University
1025 - Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Xiaolei Wei
Favorite
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Xiaolei Wei
Favorite
Wei, Yongqiang

Department of Hematology, Nanfang Hospital, Southern Medical University
1025 - Curcumin enhances ibrutinib induced killing effect against TP53-mutated Chronic Lymphocytic Leukemia cells in vitro
Yongqiang Wei
Favorite
3009 - Orelabrutinib combined with bendamustine and obinutuzumab as the first-line treatment for chronic lymphocytic leukemia/small lymphocytic leukemia: a phase II multicenter exploratory study
Yongqiang Wei
Favorite
Wenban-Smith, Thomas

Oxford Molecular Diagnostics Centre
3001 - Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation
Thomas Wenban-Smith
Favorite
3006 - High-risk International Prognostic Score for early asymptomatic CLL (IPS-E) identifies chronic lymphocytic leukaemia at risk of progression to treatment in the OXPLORED study, a prospective observational study for early lymphoproliferative disease
Thomas Wenban-Smith
Favorite
Wendtner, Clemens

Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing
1108 - Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia
Clemens Wendtner
Favorite
West, Christopher

Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
1023 - Targeting NF-κB-inducing kinase (NIK) in chronic lymphocytic leukaemia
Christopher West
Favorite
Whitechurch, Ashley

Peter MacCallum Cancer Centre and Royal Melbourne Hospital
1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon
Ashley Whitechurch
Favorite
Wierda, William

University of Texas MD Anderson Cancer Center
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
William Wierda
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
William Wierda
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
William Wierda
Favorite
2004 - Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004
William Wierda
Favorite
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
William Wierda
Favorite
2024 - Phase 1/2 Study of Zilovertamab and Ibrutinib: Durable responses suggest a novel mechanism for synthetic lethality in TP53 aberrant disease.
William Wierda
Favorite
3003 - COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
William Wierda
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
William Wierda
Favorite
Wiestner, Adrian

Lymphoid Malignancies Section, Hematology Branch, NHLBI, NIH
1041 - Anti-FcμR Antibody Drug Conjugate as a Potential Therapeutic Agent for the Treatment of Chronic Lymphocytic Leukemia
Adrian Wiestner
Favorite
Willenbacher, Ella

Medical University of Innsbruck
1011 - In-depth molecular analysis using a multi-gene lymphoma NGS panel in lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis, differentiation of entities and may optimize rational treatment allocations
Ella Willenbacher
Favorite
Willenbacher, Wolfgang
1011 - In-depth molecular analysis using a multi-gene lymphoma NGS panel in lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis, differentiation of entities and may optimize rational treatment allocations
Wolfgang Willenbacher
Favorite
Williams, Charmelle

The University of Texas MD Anderson UTHealth Houston Graduate School of Biomedical Sciences
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Charmelle Williams
Favorite
Williams-Watley, Marquise

Mayo Clinic
1122 - Treatment Patterns and Outcomes of Patients with TP53-Mutated Chronic Lymphocytic Leukemia
Marquise Williams-Watley
Favorite
Wimmer, Bettina

SP Sundhedsdata, The Data Unit, Capital Region of Denmark
1146 - Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models
Bettina Wimmer
Favorite
Wolf, Dominik

Department of Internal Medicine V, Medical University Innsbruck
1141 - Reduced predictive value of elevated Beta-2-microglobulin plasma levels on time to first treatment in newly diagnosed CLL patients with compromised kidney function
Dominik Wolf
Favorite
Wolff, Thomas

Onkologie Lerchenfeld
1105 - SAFETY AND EFFECTIVENESS IN CLL PATIENTS TREATED WITH VENETOCLAX MONOTHERAPY IN AUSTRIA, GERMANY, AND SWITZERLAND - LONG TERM FOLLOW UP DATA
Thomas Wolff
Favorite
Won, Helen

Loxo@Lilly, Indianapolis
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Helen Won
Favorite
Woo, Timothy

King's College London
1012 - High-dimensional Single-cell Characterisation of the Chronic Lymphocytic Leukaemia Tumour Microenvironment using Imaging Mass Cytometry
Timothy Woo
Favorite
Woyach, Jennifer

Division of Hematology, Department of Internal Medicine, The Ohio State University
1004 - The PKCβ inhibitor MS-553 displays preclinical efficacy in BTK inhibitor resistant Chronic Lymphocytic Leukemia
Jennifer Woyach
Favorite
1055 - Single-cell transcriptomic analysis of CLL cells at ibrutinib plus venetoclax relapse and targeting using BCL-2/BCL-xL PROTACs PZ18753b and WH25244
Jennifer Woyach
Favorite
1120 - Single-cell RNA-seq analysis reveals distinct tumor and immunosuppressive T cell phenotypes in CLL patients treated with ibrutinib.
Jennifer Woyach
Favorite
1123 - Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter’s Transformation: A Multicenter Retrospective Study
Jennifer Woyach
Favorite
1158 - A retrospective study evaluating the sequence of BTKi and venetoclax, with a focus on toxicity
Jennifer Woyach
Favorite
2003 - Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study
Jennifer Woyach
Favorite
2008 - BRUIN CLL-314: A phase 3, open-label, randomized study of pirtobrutinib versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Jennifer Woyach
Favorite
2011 - Long-term Safety with ≥12 Months of Pirtobrutinib in Relapsed/Refractory (R/R) B-Cell Malignancies
Jennifer Woyach
Favorite
3005 - BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress)
Jennifer Woyach
Favorite
Wu, Depei

Department of Hematology, The First Affiliated Hospital of Soochow University
1059 - Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy
Depei Wu
Favorite
Wu, Jiazhu

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1008 - XPO1 inhibitor Selinexor induces heme oxygenase-1 mediated p53-dependent ferroptosis in chronic lymphocytic leukemia
Jiazhu Wu
Favorite
1017 - NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia
Jiazhu Wu
Favorite
1047 - Prognosis Analysis and Validation of Fatty Acid Metabolism-Related Signature in Chronic lymphocytic leukemia
Jiazhu Wu
Favorite
Wu, Ken

BeiGene USA, Inc.
2013 - Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Ken Wu
Favorite
Wu, Wei

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University
1102 - Integrating Multi-Omics to Reveal the Heterogeneous Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
Wei Wu
Favorite
1103 - Single-cell RNA sequencing Reveals the Spatial Heterogeneity in BTKi-Resistant Richter Transformation Patients
Wei Wu
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Wei Wu
Favorite
Wu, Yujie

Department of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University
1131 - Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Yujie Wu
Favorite
1209 - Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Yujie Wu
Favorite
Wu, Zijuan

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
1002 - m6A-modified circTET2 interacting with HNRNPC regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia
Zijuan Wu
Favorite